532 related articles for article (PubMed ID: 16625847)
1. New perspectives in the medical treatment of acromegaly.
Colao A; Pivonello R; Auriemma RS; Galdiero M; Guerra E; Milone F; De Leo M; Lombardi G
J Endocrinol Invest; 2005; 28(11 Suppl International):58-66. PubMed ID: 16625847
[TBL] [Abstract][Full Text] [Related]
2. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological management of acromegaly: a current perspective.
Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
[TBL] [Abstract][Full Text] [Related]
4. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
5. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
6. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological approach to the treatment of acromegaly.
Ezzat S
Neurosurg Focus; 2004 Apr; 16(4):E3. PubMed ID: 15191332
[TBL] [Abstract][Full Text] [Related]
8. Current and future medical treatments for patients with acromegaly.
Maffezzoni F; Formenti AM; Mazziotti G; Frara S; Giustina A
Expert Opin Pharmacother; 2016 Aug; 17(12):1631-42. PubMed ID: 27352098
[TBL] [Abstract][Full Text] [Related]
9. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
[TBL] [Abstract][Full Text] [Related]
10. Current pharmacotherapy for acromegaly: a review.
Biermasz NR; Romijn JA; Pereira AM; Roelfsema F
Expert Opin Pharmacother; 2005 Nov; 6(14):2393-405. PubMed ID: 16259571
[TBL] [Abstract][Full Text] [Related]
11. Management of endocrine disease: GH excess: diagnosis and medical therapy.
Andersen M
Eur J Endocrinol; 2014 Jan; 170(1):R31-41. PubMed ID: 24144967
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and limits of somatostatin analogs.
Petersenn S
J Endocrinol Invest; 2005; 28(11 Suppl International):53-7. PubMed ID: 16625846
[TBL] [Abstract][Full Text] [Related]
13. [Optimization of the medical treatment for acromegaly].
Díez JJ; Iglesias P
Med Clin (Barc); 2013 Apr; 140(8):360-5. PubMed ID: 23103101
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic management of acromegaly].
Metzner C; Hadziselimovic S; Grafe I; Nawroth P; Kasperk C
Med Klin (Munich); 2006 Jan; 101(1):15-23. PubMed ID: 16418810
[TBL] [Abstract][Full Text] [Related]
15. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.
Feelders RA; Hofland LJ; van Aken MO; Neggers SJ; Lamberts SW; de Herder WW; van der Lely AJ
Drugs; 2009 Nov; 69(16):2207-26. PubMed ID: 19852525
[TBL] [Abstract][Full Text] [Related]
16. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
17. [New medical treatments in pituitary adenomas].
Drutel A; Caron P; Archambeaud F
Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.
Herman-Bonert VS; Zib K; Scarlett JA; Melmed S
J Clin Endocrinol Metab; 2000 Aug; 85(8):2958-61. PubMed ID: 10946911
[TBL] [Abstract][Full Text] [Related]
19. Cabergoline in acromegaly.
Kuhn E; Chanson P
Pituitary; 2017 Feb; 20(1):121-128. PubMed ID: 28025719
[TBL] [Abstract][Full Text] [Related]
20. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]